Merck KGaA Boosts U.S. Generic Market Presence With Genpharm Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Genpharm opens office in New York headed by former Able CEO Robert Mauro.
You may also be interested in...
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Purdue Signs On To Market Labopharm's Once-Daily Tramadol
Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.
PhRMA DTC Principles Call For End Of Reminder Ads
Independent review panel will be established to handle complaints about pharmaceutical advertising.